neuroendocrine carcinoma of the digestive system
Conditions
Interventions
Arm A: Six courses of etoposide + carboplatin therapy, one course of 21 days.
Carboplatin (AUC: 5) day 1, etoposide (100 mg/m2), days 1-3
Arm B: Six courses of combination therapy with etoposide, car
Sponsors
Morizane Chigusa
Eligibility
Inclusion criteria
Inclusion criteria: 1) Histologically confirmed neuroendocrine carcinoma (NEC) (2017/2019 WHO classification). 2) Participants must have one of the following diseases. 1. The primary organ is esophagus, stomach, duodenum, small intestine, appendix, colon, rectum, gallbladder, extrahepatic bile duct (hilar and distal), ampulla of Vater, or pancreas. 2. The primary organ is liver or liver metastasis of unknown primary. 3) Participants with unresectable or recurrent NEC. 4) No evidence of brain metastasis by contrast-enhanced MRI or contrast-enhanced CT. 5) No history of systemic chemotherapy or radiotherapy for NEC. 6) No history of platinum-based anti-cancer drugs, immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4, or other antibody therapies aimed at T-cell regulation). 7) No serious tumor-related complications. 8) Age at the time of enrollment is 18 years old or older. 9) Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 10) Oral intake is possible. 11) Measurable region is not required. 12) Body weight of over 30 kg. 13) Life expectancy >=12 weeks. 14) Sufficient organ functions 15) Written consent to participate in the study has been obtained from the patient.
Exclusion criteria
Exclusion criteria: 1) Synchronous or metachronous malignancies 2) Active infection requiring systemic therapy 3) Fever of 38.0 degree Celsius or higher at the time of registration. 4) Pregnant or lactating women, women of childbearing potential, or women within 28 days after delivery or male who wish the partner to get pregnant 5) Psychiatric disease 6) Systemic steroid therapy (>10 mg/body of prednisolone) or immunosuppressive agent within 14 days. 7) Interstitial pneumonia, pulmonary fibrosis 8) Patients diagnosed with active autoimmune or inflammatory disease within 5 years. 9) Serious co-existing illness(heart failure, renal failure, liver failure, bleeding peptic ulcer, intestinal paralysis, intestinal obstruction). 10) Unstable angina pectoris within 3 weeks, or with a history of myocardial infarction within 6 months 11) Impossible to use both iodine and gadolinium due to being allergic to contrast agent. 12) Uncontrollable diabetes mellitus. 13) History of allogeneic organ transplantation. 14) History of primary immunodeficiency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free Survival, Overall Response Rate, Adverse Event Rate | — |
Contacts
Public ContactYuta Maruki
National Cancer Center Hospital
Outcome results
None listed